 |
| September
29, 2026 |
| Regional
intelligence on Drugs, Diagnostics,
Devices & Digital Health |
|
|
|
* may need subscription to view |
|
BIG4BIO
CEO WEEKLY Q&A:
Kate Torchilin, Ph.D., M.B.A., CEO and
President, Mirai Bio |
| In
this CEO Q&A, Torchilin discusses the
delivery bottleneck that inspired Mirai's
founding, what differentiates its
integrated LNP platform, the milestone
that took a partner program from concept
to IND-enabling studies in under ten
months, and leading within the Flagship
Pioneering ecosystem. More |
|
|
- Aldeyra Therapeutics: Intent to Submit
Formal Dispute Resolution Request for
Reproxalap to Treat Dry Eye Disease More
- Azurity Pharmaceuticals: Receives FDA
Approval for Lamlique (lamotrigine) Oral
Suspension More
- Corbus Pharmaceuticals: First Patient Dosed
in TEMPO-1 Registrational Study of CRB-701 in
Patients With 2L+ Oropharyngeal Cancer More
- Ginkgo Datapoints and Apheris: Welcome
AbbVie, argenx, Lundbeck, and Takeda as
Founding Members of the Antibody
Developability Consortium More
- ORYZON: Receives European Medicines Agency
Approval to Initiate the HOPE-2 Phase II Study
of Vafidemstat for the Treatment of
Phelan-McDermid Syndrome (PMS) More
- Rejoni: Receives FDA Approval of the Juveena
Hydrogel System to Reduce Intrauterine
Adhesions Following Hysteroscopic Adhesiolysis
More
- Tectonic Therapeutic: Favorable Phase 1
Safety, Tolerability and PK Results for
TX2100, a Novel Approach for the Treatment of
Hereditary Hemorrhagic Telangiectasia (HHT) More
- Tiziana Life Sciences: First Participants
Dosed in ALS BANYAN Clinical Trial of
Intranasal Foralumab More
- TransCode: Continued Disease Stabilization
and Extended Treatment Duration With TTX-MC138
in Ongoing Phase 1a Clinical Trial Follow-Up More
- Tremont AI: Emerges From Stealth to Bring
Multimodal AI to Preclinical Drug Safety More
- uniQure: Additional Data From Ongoing Phase
I/II Studies of ifezuntirgene inilparvovec
(AMT-130) in Huntington’s Disease Showing
Continued Slowing of Disease Progression More
- VectorY: Expands PIONEER-ALS Phase 1/2
Clinical Trial Size More
- Verastem Oncology: Publication in
Gynecologic Oncology of Two-Year Median
Follow-Up Data From RAMP 201 Study of AVMAPKI
FAKZYNJA CO-PACK (avutometinib capsules;
defactinib tablets) in Recurrent Low-Grade
Serous Ovarian Cancer More
- Vor Bio: Telitacicept Demonstrates Deep and
Durable Minimal Symptom Expression
Through 48 Weeks in Generalized Myasthenia
Gravis More
- Zifo: Unveils AI-Driven Scientific Semantic
Layer Vision for Biopharma More
- ZOLL:
Launches Anything Can Happen. Anyone Can Help.
in the UK to Encourage Bystanders to Help in
Cardiac Emergencies More
|
|
 |
 |
CRCFO
Advisory
Reassessing your business plan?
We provide financial leadership.
Smart. Nimble. Flexible. |
|
Learn More
→ |
|
|
- Eccogene: Receives $50 Million Milestone
Payment From AstraZeneca Following
Initiation of Global Phase 3 Program for
Elecoglipron (AZD5004/ECC5004) More
- Genentech: Breaks Ground on $750 Million
Manufacturing Expansion in Hillsboro, Oregon
More
- GENFIT: First-Half 2026 Financial Results
and Provides Corporate Update More
- Harvard Launches $150M Research Initiative More
- Keros Therapeutics: Will Receive Additional
Development Milestone Payment From Partner
Takeda More
- Lifecore Biomedical: Will Be Acquired by
Webster Equity Partners More
- Precision Optics: Fourth Quarter and Fiscal
Year 2026 Financial Results More
- 38 Life Sciences Companies Land $40M in Tax
Incentives for 1,644 Mass. Jobs More*
|
|
 |
| The
future of advanced therapies:
Explore challenges and
opportunities shaping patient
access, site-of-care expansion and
commercialization. |
| Access the
Report → |
|
|
 |
Pace®
Life Sciences
The CDMO That Takes You Further.
Your partner for Product
Development, Manufacturing,
Analytical Testing, Regulatory
Consulting & Operational
Support. |
|
Learn More
→ |
|
|
- Big4Bio CEO Weekly Q&A: Kate
Torchilin, Ph.D., M.B.A., CEO and President,
Mirai Bio More
- Biotech & Pharma Updates | September 28,
2026 More
- Growing and Scaling a Radiopharmaceuticals
Company With AdvanCell's Philina Lee, Ph.D. Podcast
- Old Hearts Age Backwards: Transplanted
Organs Adjust to Host's Biological Age More*
- Some Pancreatic Cells Are Just One Genetic
Tweak Away From Treating Diabetes More
- Subscribe to LifeSci Startup for
Updates on US Startups More
- The Biotech Startups Podcast: How Teaching
High School Prepares You to Run a Company Podcast
|
|
 |
- Elucid: Appoints Mark Miller as Chief
Revenue Officer to Lead Commercial Expansion
Ahead of BioIntegrated FFR-CT Launch More
- ICYMI: Hemab Therapeutics: Strengthens Board
of Directors With Appointment of Keli Walbert
More
- ICYMI: Kirk Taylor Resigns From
Massachusetts Life Sciences Center After Two
Years More*
- ICYMI: Xilio Therapeutics Appoints Yariv J.
Houvras, M.D., Ph.D. as Chief Medical Officer
More
- Institute for Protein Innovation:
Appoints Kevin J. Harvey, Ph.D., as
President and Chief Executive Officer More
- OPPORTUNITY: Vice President, Business
Development, Remote More
- OPPORTUNITY: Director of Compliance, Remote
More
- Slone Partners: Beyond the Org Chart
- Redefining Leadership Roles After an
Acquisition More
|
|
|
DISCOVER COMPANIES |
|
Big4Bio: Boston Life Science
Company Directory |
|
Locate a specific company or
explore new companies in life
science. |
|
Explore
our Company Directory
|
Provided courtesy
of
 |
|
|
|
 |
|
|
|
You are
receiving this email because
you signed up for one of our
newsletters at Big4Bio.com,
signed up at one of our
partner or sponsor events,
or given as a gift
subscription by your firm or
organization. Unsubscribe
Big4Bio:Boston,
all rights reserved 2026
© 2026
Big4Bio, a division of
BigBio Communications. All
rights reserved.
|
|
|
|
|
